Scholar Rock Holding Corporation (SRRK)
After hours:
| Previous Close | 15.06 |
| Open | 15.00 |
| Bid | 14.68 x 600 |
| Ask | 14.77 x 100 |
| Day's Range | 13.96 - 15.15 |
| 52 Week Range | 5.56 - 21.17 |
| Volume | |
| Avg. Volume | 837,816 |
| Market Cap | 1.172B |
| Beta (5Y Monthly) | 0.89 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Scholar Rock Reports First Quarter 2024 Financial Results and Highlights Business Progress
CAMBRIDGE, Mass., May 07, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today reported financial results and corporate updates for the first quarter ended March 31, 2024.
- Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., April 12, 2024--Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 45,000 shares of its common stock to two newly hired employees, consisting of inducement stock options to purcha
- Business Wire
Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress
CAMBRIDGE, Mass., March 19, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today reported financial results and corporate updates for the full year ended December 31, 2023.
